Skip to main content
. 2010 Dec 12;2010:137320. doi: 10.1155/2010/137320

Table 1.

Patients followed.

No. Gender Age1 Treatment Hematologic
Mo2 Drug Dosage/d WBC × 109/L Lympho × 109/L Hb (gr/L) Trc × 109/L HR3 CCR3
(1) F 55 0 dg, HU 2000 mg 302.6 4.60 89 413 19 No
8 IFN 5 MIU 16.2 1.45 130 188
16 IFN 5 MIU 69.0 3.43 131 442
22 IM 400 mg 10.5 2.86 124 399
27 IM 400 mg 7.4 1.93 120 505
39 IM 600 mg 4.0 1.11 120 175
58 DS 100 mg 2.1 0.89 119 139
(2) F 62 0 dg, HU 2500 mg 120.0 3.54 132 226 6 19
6 IFN 3 MIU 4.7 1.49 151 163
14 IFN 3 MIU 5.1 1.20 131 352
15 IFN 5 MIU 5.8 0.91 140 356
25 IM 400 mg 3.2 1.12 138 157
43 IM 400 mg 7.0 1.38 130 430
56 IM 400 mg 9.3 1.61 130 648
(3) M 40 0 dg, HU 3000 mg 21.9 2.07 168 327 8 26
7 IFN 3 MIU 8.1 1.08 163 262
15 IFN 5 MIU 3.1 0.85 160 125
26 IM 400 mg 4.2 1.10 146 246
43 IM 400 mg 4.5 1.37 147 209
58 IM 400 mg 3.9 1.01 158 210
(4) M 60 0 dg, HU 2000 mg 198.5 5.06 110 550 6 36
6 IFN 3 MIU 3.4 0.86 132 115
12 IFN 5 MIU 3.4 1.21 137 152
42 IM 400 mg 5.5 1.52 131 301
56 IM 400 mg 3.5 1.56 136 311
(5) M 33 0 dg, HU 2500 mg 99.7 5.91 142 169 2 40
6 HU 2000 mg 9.9 3.56 145 151
9 IFN 3 MIU 47.8 3.12 137 102
40 IM 400 mg 4.3 1.69 142 202
53 IM 400 mg 5.5 2.01 140 258
58 IM 400 mg 6.6 1.88 136 266
(6) F 35 0 dg, IFN 3 MIU 107.5 0.48 117 276 2 35
10 IFN 3 MIU 4.4 0.76 101 182
12 IM 400 mg 2.8 1.12 102 145
36 DS 100 mg 2.9 1.61 89 233
48 DS 100 mg 2.8 1.83 89 331
(7) M 54 0 dg, HU 2000 mg 16.4 4.86 136 595 11 38
7 HU 2000 mg 4.5 5.71 137 532
20 HU 1000 mg 5.5 3.21 134 209
34 IM 400 mg 6.9 1.23 134 206
47 IM 400 mg 6.8 2.19 132 236
(8) F 43 0 dg, IM 400 mg 26.9 4.05 144 464 2 17
2 IM 400 mg 8.3 1.66 129 228
9 IM 400 mg 6.0 1.76 123 185
17 IM 400 mg 7.5 1.26 126 207
31 IM 300 mg 7.6 1.73 120 239
45 IM 300 mg 8.3 1.45 125 315
(9) M 48 0 dg, IM 400 mg 439.2 6.16 81 184 7 No
30 IM 400 mg 4.4 1.96 150 117
44 IM 400 mg 5.4 1.41 149 112
(10) F 38 0 dg, IM 400 mg 328.6 1.81 88 614 5 27
7 IM 400 mg 3.0 1.32 121 200
28 IM 400 mg 3.3 1.10 94 212
36 IM 400 mg 4.9 0.98 103 236
(11) F 61 0 dg,HU 2000 mg 16.8 5.31 109 1895 4 25
29 DS 100 mg 5.8 2.02 100 519
52 DS 100 mg 5.4 2.75 104 249

1Age at enrollment; 2Mo: month; WBC: white blood cell count; Hb: hemoglobin; and Trc, thrombocyte count; HU: hydroxyurea; IFN: interferon-alpha 2a; IM: imatinib mesylate; DS: dasatinib; MIU, Millions International Units. 3The figure indicates month after diagnosis at which HR or CCR was first observed; “no” means that CCR was not achieved.

Notes: Patient no. 1 developed vasculitis (erythema nodosum), neutropenia which was subsequently treated with growth factors and immunoglobulins. Patients 6 and 7 had laboratory tests positive for autoimmune thyroiditis without any clinical manifestations.

Patient no. 11 decided to undergo homeopathic therapy and self-therapy with HU and was out of the evidence for some time. At the indicated interval, DS therapy was started because of pathological findings both in peripheral blood and bone marrow.